BMED Fact Sheet: iShares Health Innovation Active ETF
Share
$34.31
close, Nov 20, 2026
Over the year to Nov 19, 2026, BMED returned +18.6% in total and charged 0.55% a year.
- 1-year total return
- +17.5%
- to Nov 20, 2026
- Expense ratio
- 0.55%
- a year
- Net assets
- $14m
- on Nov 19, 2026
- Net flow, last 5 trading days
- $0
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
BMED $11,855 +18.6% · ACWI $10,902 +9.0% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−3.8%
3 months−0.8%
Year to date+13.5%
1 year+17.5%
3 years+56.6%
5 years+18.5%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
GILEAD SCIENCES6.01%
DANAHER5.22%
ABBVIE4.91%
MODERNA4.83%
THERMO FISHER SCIENTIFIC4.41%
EDWARDS LIFESCIENCES4.35%
BIOGEN3.82%
METTLER-TOLEDO INTERNATIONAL INC3.73%
IQVIA HOLDINGS INC3.50%
VERTEX PHARMACEUTICALS3.35%
BMED top ten by weight, 44.1% of the fund, of its 55 equity positions, from the holdings published by its issuer for Nov 18, 2026.
Facts
Holds 55 stocks in healthcare innovation and GLP-1, 60% of its weight in S&P 500 companies · First traded Oct 1, 2020 · Benchmark Its own holdings, as of Nov 18, 2026